Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 35, 2024 - Issue 1
Submit an article Journal homepage
735
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Apremilast for the treatment of pustular psoriasis induced by neoadjuvant ifosfamide + etoposide chemotherapy for Ewing Sarcoma: a case report

Mario Valentia Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, Humanitas Research Hospital IRCCS, Rozzano, ItalyView further author information
,
Luigi Gargiuloa Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, Humanitas Research Hospital IRCCS, Rozzano, ItalyView further author information
,
Luciano Ibbaa Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, Humanitas Research Hospital IRCCS, Rozzano, ItalyCorrespondence[email protected]
View further author information
,
Alexia Bertuzzic Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, ItalyView further author information
,
Sofia Manarad Pathology Unit, Humanitas Research Hospital IRCCS, Rozzano, ItalyView further author information
,
Francesco Tosoa Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, Humanitas Research Hospital IRCCS, Rozzano, ItalyView further author information
,
Antonio Costanzoa Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, Humanitas Research Hospital IRCCS, Rozzano, ItalyView further author information
&
Alessandra Narcisib Dermatology Unit, Humanitas Research Hospital IRCCS, Rozzano, ItalyView further author information
 show all
Article: 2319303 | Received 08 Feb 2024, Accepted 09 Feb 2024, Published online: 20 Feb 2024

References

  • Shi VJ, Levy LL, Choi JN. Cutaneous manifestations of nontargeted and targeted chemotherapies. Semin Oncol. 2016;43(3):1–3. doi:10.1053/j.seminoncol.2016.02.018.
  • Anderton J, Moroz V, Marec-Bérard P, et al. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 protocol. Trials. 2020;21(1):96. Published 2020 Jan 17. doi:10.1186/s13063-019-4026-8.
  • European Medicines Agency. Otezla (apremilast): summary of product characteristics. 2015 [cited 2023 December 6]. https://www.ema.europa.eu/en/medicines/human/EPAR/otezla.
  • Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–1268. doi:10.1016/j.jaad.2020.03.132.
  • Brennan B, Kirton L, Marec-Bérard P, et al. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. Lancet. 2022;400(10362):1513–1521. Oct 29 doi:10.1016/S0140-6736(22)01790-1.
  • Ilari I, De Ioris MA, Milano GM, et al. Toxicity of high-dose chemotherapy with etoposide, thiotepa and CY in treating poor-prognosis Ewing’s sarcoma family tumors: the experience of the Bambino Gesù Children’s Hospital. Bone Marrow Transplant. 2010;45(8):1274–1280. doi:10.1038/bmt.2009.353.
  • Pavia G, Gargiulo L, Cortese A, et al. Apremilast for the treatment of palmo-plantar non-pustular psoriasis: a real-life single-center retrospective study. Dermatol Ther. 2022;35(2):e15253. Feb doi:10.1111/dth.15253.
  • Ständer S, Syring F, Ludwig RJ, et al. Successful treatment of refractory palmoplantar pustular psoriasis with apremilast: a case series. Front Med (Lausanne). 2020;7:543944. doi:10.3389/fmed.2020.543944.
  • Valenti M, Pavia G, Gargiulo L, et al. Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population. J Dermatolog Treat. 2022;33(3):1638–1642. doi:10.1080/09546634.2021.1886231.
  • Gargiulo L, Pavia G, Valenti M, et al. Safety of biologic therapies in patients with moderate-to-severe plaque psoriasis and concomitant viral hepatitis: a monocentric retrospective study. Dermatol Ther (Heidelb). 2022;12(5):1263–1270. doi:10.1007/s13555-022-00726-w.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.